The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 01, 2022

Filed:

Sep. 29, 2016
Applicant:

The University of Chicago, Chicago, IL (US);

Inventors:

Jeffrey A. Hubbell, Chicago, IL (US);

David Scott Wilson, Chicago, IL (US);

Sachiko Hirosue, Chicago, IL (US);

Assignee:

The University of Chicago, Chicago, IL (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 47/58 (2017.01); A61K 39/015 (2006.01); A61K 39/39 (2006.01); A61K 31/787 (2006.01); A61K 47/54 (2017.01); C08F 8/00 (2006.01); C07D 471/04 (2006.01); A61P 35/00 (2006.01); A61P 33/06 (2006.01); A61K 39/145 (2006.01); C08F 220/56 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/58 (2017.08); A61K 31/787 (2013.01); A61K 39/015 (2013.01); A61K 39/145 (2013.01); A61K 39/39 (2013.01); A61K 47/549 (2017.08); A61P 33/06 (2018.01); A61P 35/00 (2018.01); C07D 471/04 (2013.01); C08F 8/00 (2013.01); C08F 220/56 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/55577 (2013.01); A61K 2039/55583 (2013.01); A61K 2039/572 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6087 (2013.01); A61K 2039/6093 (2013.01); A61K 2039/627 (2013.01); C08F 2438/03 (2013.01);
Abstract

Monomers and copolymers are provided that both target antigen presenting cells (APCs) and activate toll-like receptor (TLR) on the APCs. In some embodiments, compositions and methods involve a polymer that targets the mannose receptor on APCs, in addition to activating a TLR. These can then be conjugated to protein antigens to efficiently target antigens to DCs and simultaneously induce the up-regulation of co-stimulatory molecules that are essential for effective T cell activation. This copolymer is a more efficient activator of DCs, as measured by the surface expression of co-stimulatory molecules and the release of proinflammatory cytokines, than the monomeric form the TLR agonist used in the polymer formulation. Aspects of the disclosure relate to novel compounds, methods, and compositions for treating diseases using the compounds, copolymers, and compositions described herein.


Find Patent Forward Citations

Loading…